Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Shares Outstanding (2022 - 2025)

Entrada Therapeutics has reported Shares Outstanding over the past 4 years, most recently at $38.3 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $38.3 million for Q4 2025, up 1.86% from a year ago — trailing twelve months through Dec 2025 was $38.3 million (up 1.86% YoY), and the annual figure for FY2025 was $38.3 million, up 1.86%.
  • Shares Outstanding for Q4 2025 was $38.3 million at Entrada Therapeutics, roughly flat from $38.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for TRDA hit a ceiling of $38.3 million in Q4 2025 and a floor of $31.3 million in Q1 2022.
  • Median Shares Outstanding over the past 4 years was $33.5 million (2023), compared with a mean of $34.8 million.
  • Biggest five-year swings in Shares Outstanding: rose 1.42% in 2024 and later rose 12.91% in 2025.
  • Entrada Therapeutics' Shares Outstanding stood at $31.4 million in 2022, then rose by 6.51% to $33.4 million in 2023, then increased by 12.41% to $37.6 million in 2024, then grew by 1.86% to $38.3 million in 2025.
  • The last three reported values for Shares Outstanding were $38.3 million (Q4 2025), $38.2 million (Q3 2025), and $38.0 million (Q2 2025) per Business Quant data.